Synonym
Adimolol hydrochloride hydrate, Men 935; MEN935; MEN-935
IUPAC/Chemical Name
2H-Benzimidazol-2-one, 1,3-dihydro-1-(3-((2-hydroxy-3-(1-naphthalenyloxy)propyl)amino)-3-methylbutyl)-, monohydrochloride, monohydrate
InChi Key
ADETVRISJJRVMM-UHFFFAOYSA-N
InChi Code
InChI=1S/C25H29N3O3.ClH.H2O/c1-25(2,14-15-28-22-12-6-5-11-21(22)27-24(28)30)26-16-19(29)17-31-23-13-7-9-18-8-3-4-10-20(18)23;;/h3-13,19,26,29H,14-17H2,1-2H3,(H,27,30);1H;1H2
SMILES Code
O=C1NC2=CC=CC=C2N1CCC(C)(NCC(O)COC3=C4C=CC=CC4=CC=C3)C.[H]Cl.[H]O[H]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
MEN935, also known as Adimolol hydrochloride hydrate, is an antihypertensive agent and a β-adrenoceptor blocker.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
474.00
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
TBD
1: Arrigoni J, Lambrecht JT. [Complications during and after third molar extraction]. Schweiz Monatsschr Zahnmed. 2004;114(12):1271-86. French, German. PubMed PMID: 15646673.
2: Wyszynski DF, Waterworth DM, Barter PJ, Cohen J, Kesäniemi YA, Mahley RW, McPherson R, Waeber G, Bersot TP, Sharma SS, Nolan V, Middleton LT, Sundseth SS, Farrer LA, Mooser V, Grundy SM. Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). Am J Cardiol. 2005 Jan 15;95(2):194-8. PubMed PMID: 15642551.
3: Eikelis N, Lambert G, Wiesner G, Kaye D, Schlaich M, Morris M, Hastings J, Socratous F, Esler M. Extra-adipocyte leptin release in human obesity and its relation to sympathoadrenal function. Am J Physiol Endocrinol Metab. 2004 May;286(5):E744-52. Epub 2004 Jan 13. PubMed PMID: 14722031.
4: Palluk R, Hoefke W, Gaida W, Mierau J, Bechtel WD. Interactions of MEN 935 (adimolol), a long acting beta- and alpha-adrenolytic antihypertensive agent, with postsynaptic alpha-adrenoceptors in different isolated blood vessels--influence of angiotensin II. Naunyn Schmiedebergs Arch Pharmacol. 1986 Jul;333(3):277-83. PubMed PMID: 3020439.
5: Wiedemann I, Peil H, Justus H, Adamus S, Brantl V, Lohmann H. Pharmacokinetics of adimolol after single and multiple dose administration in healthy volunteers. Arzneimittelforschung. 1985;35(6):964-9. PubMed PMID: 2862877.
6: Wiedemann I. High-performance liquid chromatographic determination of MEN 935 in human plasma, a highly specific and sensitive analytical method for a new antihypertensive drug. Arzneimittelforschung. 1983;33(6):861-4. PubMed PMID: 6684441.
